Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Capital Expenditures (2016 - 2025)

Marimed (MRMD) has disclosed Capital Expenditures for 12 consecutive years, with $33000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 96.88% to $33000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, down 53.81% year-over-year, with the annual reading at $1.2 million for FY2025, 90.24% down from the prior year.
  • Capital Expenditures for Q4 2025 was $33000.0 at Marimed, down from $1.3 million in the prior quarter.
  • The five-year high for Capital Expenditures was $12.1 million in Q4 2022, with the low at -$4.5 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $1.9 million, with a median of $1.3 million recorded in 2022.
  • The sharpest move saw Capital Expenditures skyrocketed 1310.26% in 2022, then crashed 136.7% in 2023.
  • Over 5 years, Capital Expenditures stood at $3.2 million in 2021, then surged by 276.43% to $12.1 million in 2022, then plummeted by 136.7% to -$4.5 million in 2023, then surged by 123.75% to $1.1 million in 2024, then crashed by 96.88% to $33000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $33000.0, $1.3 million, and $1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.